Please assess the completion status of the following clinical trial:

Trial Title: Donepezil and the Risk of Falls in Seniors With Cognitive Impairment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 65-100~* Male or Female~* Having Mild Cognitive Impairment (diagnosed using criteria validated by Petersen et. al)~* Acceptable Body Mass Index (BMI) range: 18-30~* Acceptable blood pressure (Systolic: 110-160, Diastolic: 50-110)~* Able to walk independently 10 meters without any gait aid~* Able to travel to Aging Brain and Memory Clinic for the assessments~Exclusion Criteria:~* Unable to understand English~* Low body weight (less than 99lb/45kg)~* Possible diagnosis of Alzheimer's Disease~* Use of herbal preparations such as St. John's Wort and ginko biloba~* History of drug or alcohol abuse/dependence~* History of psychiatric illness within the last two years, including depression~* Parkinsonism or any neurological disorder with residual motor deficit (e.g.: stroke, epilepsy)~* Musculoskeletal disorder detected by clinical examination which affects gait performance~* Active osteoarthritis affecting the lower limbs (American College of Rheumatology criteria)~* Use of psychotropic medication, which can affect motor performance~* Use of an anticholinergic agent (benztropines), other acetylcholinesterase inhibitors or cholinergic agents (bethanechol)~* Depression (score above 8/15 on the Geriatric Depression Scale - GDS)~* Comorbidities which may contradict use of ChEIs~* History of chronic bradycardia or sick sinus syndrome~* Severe COPD and/or asthma~* History of seizure disorders

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Donepezil (Type: EXPERIMENTAL): participants with MCI receiving donepezil
- Placebo (Type: PLACEBO_COMPARATOR): Participants with MCI receiving placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).